Turning Microbes into Cancer Therapeutics
Turning Microbes into Cancer Therapeutics
Turning Microbes into Cancer Therapeutics
Laguna creates unique therapies to address refractory cancers by designing cellular microbial therapies that activate powerful innate immune cells
Laguna creates unique therapies to address refractory cancers by designing cellular microbial therapies that activate powerful innate immune cells
Laguna creates unique therapies to address refractory cancers by designing cellular microbial therapies that activate powerful innate immune cells
WHY CANCERS PERSIST
Cancers evade the immune system
Tumors often develop ways to hide from or suppress the immune system, limiting the effectiveness of many current immunotherapies. While treatments like checkpoint inhibitors and engineered T-cell therapies have transformed care for some patients, many cancers remain resistant including high-risk leukemias (AML, ALL), soft-tissue sarcomas, and various solid tumors.
Tumors often develop ways to hide from or suppress the immune system, limiting the effectiveness of many current immunotherapies. While treatments like checkpoint inhibitors and engineered T-cell therapies have transformed care for some patients, many cancers remain resistant including high-risk leukemias (AML, ALL), soft-tissue sarcomas, and various solid tumors.
Many immunotherapies work for only a subset of patients
Cell therapies can be complex and difficult to scale
SOLVING IMMUNE EVASION
The QUAIL Platform
QUAIL was designed to overcome these challenges by activating a powerful innate immune response inside the body.
Engineered microbe
Activation of innate T cells
Immune attack on tumors
Engineered Microbial Platform
The QUAIL Platform is the foundation of a pipeline of highly attenuated microbes that cannot grow or survive except within the very immune cells that drive strong, unique, and durable innate T cell responses.
Activating Innate T Cells
Laguna’s pipeline of therapies built from the QUAIL Platform specifically activate and expand innate T cells including γδ T cells and MAIT cells, which are uniquely capable of recognizing and eliminating cancers such as high-risk leukemias (AML, ALL), soft-tissue sarcomas, and various solid tumors that are difficult to treat with existing therapies.
In Vivo Immunotherapy
QUAIL-100 activates an immune response directly inside the body and directs them to AML and ALL leukemic blasts, avoiding the complexity of ex vivo cell engineering and simplifying CAR-T therapy.
Engineered Microbial Platform
The QUAIL Platform is the foundation of a pipeline of highly attenuated microbes that cannot grow or survive except within the very immune cells that drive strong, unique, and durable innate T cell responses.
Activating Innate T Cells
Laguna’s pipeline of therapies built from the QUAIL Platform specifically activate and expand innate T cells including γδ T cells and MAIT cells, which are uniquely capable of recognizing and eliminating cancers such as high-risk leukemias (AML, ALL), soft-tissue sarcomas, and various solid tumors that are difficult to treat with existing therapies.
In Vivo Immunotherapy
QUAIL-100 activates an immune response directly inside the body and directs them to AML and ALL leukemic blasts, avoiding the complexity of ex vivo cell engineering and simplifying CAR-T therapy.
Engineered Microbial Platform
The QUAIL Platform is the foundation of a pipeline of highly attenuated microbes that cannot grow or survive except within the very immune cells that drive strong, unique, and durable innate T cell responses.
Activating Innate T Cells
Laguna’s pipeline of therapies built from the QUAIL Platform specifically activate and expand innate T cells including γδ T cells and MAIT cells, which are uniquely capable of recognizing and eliminating cancers such as high-risk leukemias (AML, ALL), soft-tissue sarcomas, and various solid tumors that are difficult to treat with existing therapies.
In Vivo Immunotherapy
QUAIL-100 activates an immune response directly inside the body and directs them to AML and ALL leukemic blasts, avoiding the complexity of ex vivo cell engineering and simplifying CAR-T therapy.
Pipeline
Our pipeline applies the QUAIL Platform across multiple cancer settings
Hematologic Programs
Hematologic Programs
Hematologic Programs
QUAIL 100 / 120
AML, Multiple Myeloma
Solid Tumor Programs
Solid Tumor Programs
Solid Tumor Programs
QUAIL 120 / 400 / 700
Sarcoma, MSS CRC
Platform Expansion
Platform Expansion
Platform Expansion
QUAIL 120
Infectious Diseases
Our Partners
REIMAGINING IMMUNOTHERAPY
Our mission is to create the most effective cancer therapies by harnessing the natural strength of microbes to drive powerful, durable, and targeted in vivo immune therapy.
Laguna is a biotechnology company developing next-generation microbial platforms designed to activate innate immune responses against cancer. By combining insights from microbiology and immunology, the company is building a new class of immunotherapies designed to be safer, scalable, and effective across multiple cancer types.
REIMAGINING IMMUNOTHERAPY
Our mission is to create the most effective cancer therapies by harnessing the natural strength of microbes to drive powerful, durable, and targeted in vivo immune therapy.
Laguna is a biotechnology company developing next-generation microbial platforms designed to activate innate immune responses against cancer. By combining insights from microbiology and immunology, the company is building a new class of immunotherapies designed to be safer, scalable, and effective across multiple cancer types.
REIMAGINING IMMUNOTHERAPY
Our mission is to create the most effective cancer therapies by harnessing the natural strength of microbes to drive powerful, durable, and targeted in vivo immune therapy.
Laguna is a biotechnology company developing next-generation microbial platforms designed to activate innate immune responses against cancer. By combining insights from microbiology and immunology, the company is building a new class of immunotherapies designed to be safer, scalable, and effective across multiple cancer types.
Copyright © 2026 Laguna Biotherapeutics Inc.
All rights reserved.
FOLLOW US
